Pembrolizumab and Lenvatinib for Advanced Well-Differentiated Neuroendocrine Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
ESMO Open 2024 Apr 01;9(4)102386, T Al-Toubah, MJ Schell, B Morse, M Haider, T Valone, J StrosbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.